Chest doctors issue guidelines for CT lung cancer screening

An expert panel of chest physicians has updated its guidelines for low-dose...Read more on AuntMinnie.comRelated Reading: New solid nodules may increase lung cancer risk Canadian risk model boosts CT lung screening efficiency Study: CT screening would cut lung cancer deaths in China ARRS: Do NLST results translate to the real world? BMJ: Benefits of CT lung cancer screening outweigh dose
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Women who have never smoked, especially Asian women, are highly susceptible to develop lung cancer if exposed to high levels of air pollution.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
AstraZeneca's immunotherapy drug Imfinzi cut the risk of death in patients with mid-stage lung cancer by nearly a third in a closely watched clinical study, reinforcing the case for using the drug in earlier disease.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
A drug cocktail with Roche's Tecentriq added two months to small-cell lung cancer patients' lives, according to a study, aiding the Swiss group's bid to win approval in a niche disease area before rivals that now dominate the immunotherapy market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
A drug cocktail with Roche's Tecentriq added two months to small-cell lung cancer patients' lives, potentially aiding the Swiss company's bid to win approval in a niche disease area before rivals that now dominate the immunotherapy market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
AstraZeneca's immunotherapy drug Imfinzi cut the risk of death in patients with mid-stage lung cancer by nearly a third in a closely watched clinical study, reinforcing the case for using the drug in earlier disease.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Authors: Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M Abstract BACKGROUND: Programmed cell death-ligand 1 (PD-L1) is a checkpoint receptor that facilitates immune evasion by tumor cells, through interaction with programmed cell death-1 (PD-1), a receptor expressed by T-cells. Durvalumab is an anti-PD-L1 monoclonal antibody that blocks PD-L1 interaction with PD-1 on T-cells, countering the tumor's immune-evading tactics. Phase I/II studies demonstrated durable responses and manageable tolerability in heavily pre-treated patients with non-sma...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
AstraZeneca's immunotherapy drug Imfinzi has been approved in Europe for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body, the drugmaker said on Monday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Over the past decade, lung cancers have exhibited a disproportionately high mortality and increasing mortality trend in Thailand, especially in the northern region, and prevention strategies have consequently ...
Source: BMC Public Health - Category: Consumer Health News Authors: Tags: Research article Source Type: research
Abstract Epithelial-to-mesenchymal transition (EMT) is a dynamic transitional state from the epithelial to mesenchymal phenotypes. Numerous studies have suggested that EMT and its intermediate states play important roles in tumor invasion and metastasis. To identify novel regulatory molecules of EMT, we screened a siRNA library targeting human 720 kinases in A549 lung adenocarcinoma cells harboring E-cadherin promoter-luciferase reporter vectors. NIMA-related kinase-4 (NEK4) was identified and characterized as a positive regulator of EMT in the screening. Suppression of NEK4 resulted in the inhibition of cell migr...
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tags: J Cell Mol Med Source Type: research
CONCLUSIONS: TRKA expression can be found in 1.6% of solid tumours and can be paralleled by NTRK1 gene rearrangements or mostly GCN gain. The prognostic and translational therapeutic impact of the latter remains to be established. PMID: 29802225 [PubMed - indexed for MEDLINE]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Pathol Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | China Health | Lung Cancer | Radiology | Study